vinorelbine (Navelbine)

1.	Gebbia, Vittorio: 10 articles (09/2008 - 01/2002)
2.	Goldhirsch, A: 9 articles (12/2007 - 01/2000)
3.	Gridelli, Cesare: 9 articles (10/2007 - 04/2002)
4.	Lorusso, V: 9 articles (06/2006 - 01/2000)
5.	Perng, Reury-Perng: 8 articles (08/2008 - 04/2003)
6.	Chen, Yuh-Min: 8 articles (08/2008 - 04/2003)
7.	Comella, P: 8 articles (02/2007 - 02/2000)
8.	Frasci, G: 8 articles (02/2007 - 01/2000)
9.	Georgoulias, V: 8 articles (10/2006 - 01/2001)
10.	Nolè, F: 7 articles (12/2007 - 01/2000)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/1999 - "BACKGROUND: Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment" 05/01/1998 - "BACKGROUND: Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment" 04/01/2006 - "In addition,we explain why it took 17 years for vinorelbine to be approved despite the fact that as early as the beginning of development, it was scientifically proven to be very useful in patients with breast cancer, and that the new drug application was submitted in 1993" 01/01/2001 - "Vinorelbine has proven to be effective in pretreated metastatic breast cancer patients" 03/01/1997 - "Vinorelbine is effective in pretreated advanced breast cancer patients." Get all the results and reference details, order at left...
2.	Small Cell Carcinoma (Small Cell Lung Cancer) 07/01/2000 - "There is a high level of evidence that vinorelbine is an effective agent for the treatment of non-small-cell lung cancer." 04/01/1999 - "Vinorelbine is a semisynthetic vinca alkaloid that is effective against advanced non-small cell lung cancer (NSCLC)" 10/01/1999 - "Combinations of vinorelbine with other nonplatinum agents show promising results in phase I and phase II trials in non-small cell lung cancer (NSCLC)" 10/01/1994 - "Moreover, trials that are documenting the efficacy of vinorelbine in small cell lung cancer are just beginning." 04/01/2007 - "Efficacy of vinorelbine in the second-line setting and beyond in non-small cell lung cancer." Get all the results and reference details, order at left...
3.	Neoplasms (Cancer) 11/01/2000 - "In both patients, vinorelbine treatment improved several clinical indicators of cancer symptomatology including serum LDH, levels of other clinical blood tests, as well as a subjective assessment of the quality of life (QOL)" 08/01/2006 - "The objectives of this study in four medical institutions were to evaluate DLT (Dose Limiting Toxicity) and safety as primary endpoints, and tumor response and pharmacokinetics of vinorelbine as secondary endpoints" 06/15/2002 - "Due to the few cases considered here, further Phase II studies are needed to establish a potential role of vinorelbine in the treatment of these tumors." 01/01/2002 - "Thus, in this study, the comparative blood/plasma pharmacokinetics of vinorelbine were investigated in 15 elderly patients with advanced metastatic cancer" 11/01/2001 - "Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors." Get all the results and reference details, order at left...
4.	Carcinoma (Carcinomatosis) 01/01/1993 - "KW-2307 and VDS were also effective in inhibiting the growth of 2 human breast carcinomas (MX-1 and Br-10)." 06/01/2007 - "Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial." 10/01/1999 - "The purpose of this study was to determine the efficacy of vinorelbine given by 96-hour continuous infusion to patients with refractory metastatic breast carcinoma patients" 08/01/2005 - "A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC)." 01/01/2005 - "Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study." Get all the results and reference details, order at left...
5.	Lung Neoplasms (Lung Cancer) 11/01/2000 - "Improvement in quality of life with vinorelbine as a single agent in two patients with recurrent lung cancer]" 02/01/2005 - "These studies for the first time show that RLIP76 mediates vinorelbine transport and is capable of conferring drug accumulation defect and resistance to lung cancer cells." 11/01/2003 - "The landmark Elderly Lung Cancer Vinorelbine Italian Study Group trial and the Multicentre Italian Lung Cancer in the Elderly Study clarified the role of vinorelbine in the treatment of elderly patients" 01/01/2001 - "Elderly Lung Cancer Vinorelbine Italian Study." 01/06/1999 - "The Elderly Lung Cancer Vinorelbine Italian Study Group." Get all the results and reference details, order at left...
156 Diseases and 1348 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	gemcitabine
2.	Cisplatin (Platino)
3.	docetaxel (Taxotere)
4.	vinorelbine (Navelbine)
5.	Paclitaxel (Taxol)
6.	Fluorouracil (Carac)
7.	Epirubicin (Ellence)
8.	Carboplatin (JM8)
9.	Doxorubicin (Adriamycin)
10.	Taxoids
225 Drugs and Important Bio-Agents and 1139 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Palliative Care (Palliative Medicine)
5.	Neoadjuvant Therapy
19 Therapies and Procedures and 424 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>